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In a retrospective analysis by Wan and colleagues [1],
propensity score matching analysis showed that ulinastatin
administration was associated with a decreased incidence
of acute kidney injury (AKI) after cardiac surgery. Paradox-
ically, patient outcomes, including intensive care unit
(ICU) length of stay, in-hospital length of stay, and morta-
lity, were not significantly different between the ulinastatin
and control groups, although AKI has been significantly
associated with increased morbidity and mortality after
cardiac surgery [2].
An issue with this study is that it did not report cardio-
vascular medicine administration. It has been shown that
preoperative statin is associated with a reduced risk of
postoperative AKI and mortality in patients undergoing
elective cardiac surgery [3]. However, preopevrative use of
renin-angiotensin system inhibitors has been associated
with a 28 % increase in AKI after cardiac surgery and this
effect is independent of intraoperative and postoperative
hypotension, suggesting a role for the changes in glomeru-
lar capillary pressure induced by these drugs [4]. Similarly,
it was unclear whether the two groups were comparable
with respect to types of cardiac surgery. The risk of AKI
and mortality after cardiac surgery increases progressively
with complexity of the planned procedure, i.e., the risk is
lowest in patients undergoing coronary artery bypass
grafting only, while it increases after valve replacement
surgery and is greatest after combined coronary artery
bypass grafting and valve procedures [5]. We are con-
cerned that the lack of inclusion of these risk factors in
the propensity score matching model would have biased
the effect of ulinastatin administration on postoperative
AKI and mortality in this study.
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The protective role of statins remains a controversial
issue. On one hand, they have been shown to possess anti-
inflammatory properties by effectively reducing inflamma-
tory cytokines. However, a systemic review containing
seven randomized controlled trials did not find evidence
that preoperative statin use is associated with a reduction
in the incidence of AKI after cardiac surgery [6]. This
issue has also been discussed in Critical Care [7].
In our study, we initially took medications into
account, which included statins, phosphocreatine, non-
steroidal anti-inflammatory drugs, hydroxyethyl starch,
and mannitol. Using multiple logistic regression analysis,
our results showed no obvious protective effect of the
phosphocreatine and statins in reducing the risk of AKI
(data not shown). However, we found that ulinastatin
played a protective role in the development of cardiac
surgery-associated (CSA)-AKI after adjusting for statins
and other factors. Therefore, we further performed
propensity matching to confirm the result.
To date, the risk factors for AKI have been well studied
[8]. We do agree that the risk of developing AKI is associ-
ated with the types of cardiac surgery and the complexity
of the operation, which includes variables such as different
cardiopulmonary bypass duration, hypothermia, mean
artery pressure, transfusion, hematocrit, and so forth.
These cardinal possible risk factors were considered and
included in our study design, thus making the two groups
relatively comparable. In addition, because this is a retro-
spective study, other medications which may also have
had an impact on the development of AKI, such as antibi-
otics, diuretics, steroids, angiotensin converting enzyme
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inhibitors/angiotensin-receptor blockers, and so forth,
were not analyzed. We do acknowledge the possible
existence of bias, and thus prospective, randomized,
controlled trials with a large sample size and perioperative
administration of ulinastatin are needed to confirm the
reno-protective effect of ulinastatin in the development of
CSA-AKI.
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